Roche is a major seller of cancer drugs. Photo: Smith Collection / Gado via Getty Images

Roche is buying out the rest of Flatiron Health for $1.9 billion, the companies said Thursday. The total investment for Roche, a drug maker based in Switzerland, is about $2.1 billion in cash since it already owned about 13% of Flatiron, a tech company that handles electronic health records and data mining specifically for cancer doctors, researchers and patients.

The bottom line: Roche led Flatiron's latest funding round, which valued the company at $1.1 billion, and Roche's cancer drugs like Avastin and Herceptin represent more than 60% of its pharmaceutical sales — so it's no surprise Roche is enamored with technology that builds on its main products.

Go deeper

Houston public health system CEO says coronavirus situation is "dire"

Houston's coronavirus situation is "dire, and it's getting worse, seems like, every day," Harris Health System CEO and President Dr. Esmail Porsa said Monday on MSNBC's "Morning Joe."

The big picture: Porsa said the region is seeing numbers related to the spread of the virus that are "disproportionately higher than anything we have experienced in the past." He noted that Lyndon B. Johnson Hospital's ICU is at 113% capacity, and 75% of its beds are coronavirus patients.

Fund managers start to board the stock bandwagon

Illustration: Aïda Amer/Axios

Asset managers at major U.S. investment firms are starting to get bullish with their clients, encouraging stock buying and trying not to get left behind right as the metrics on tech stocks rise back to highs not seen since the dot-com crash of 2000.

What's happening: Appetite for stocks is starting to return, but slowly as institutional money managers were overwhelmingly sitting on the sidelines in cash during April and May.

2 hours ago - World

China bans Cruz and Rubio over Xinjiang criticism

Photos: Graeme Jennings/Pool/Getty Images; Al Drago/Pool/Getty Images

China said Monday that it will ban entry to Sens. Marco Rubio (R-Fla.) and Ted Cruz (R-Texas) over their criticisms of human rights abuses in Xinjiang, the AP reports.

The big picture: The move seems to be retaliatory after the U.S. announced sanctions on four Chinese officials for human rights abuses against Uighur Muslims and other ethnic minorities in the region last week.